Hospira Targets First U.S. Biosimilar Filing In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic specialty injectables firm expects to file a biosimilar version of Amgen’s Epogen in the U.S. in late 2014, potentially positioning it for its first U.S. biosimilar launch in late 2015.